Pharmexa obtains global license to Provax® from Biogen Idec

02-Sep-2005

Pharmexa has entered into a global, non-exclusive license to use Biogen Idec's Provax® adjuvant in Pharmexa's products. The parties have agreed not to disclose the commercial terms of the license, but conclusion of the agreement will not impact Pharmexa's expectations for the financial year 2005.

Jakob Schmidt, CEO in Pharmexa says: "In-licensing is an important part of Pharmexa's strategy, and we are very pleased that we now have broad access to Provax®. We recently expanded our license to the PADRE® epitope from Epimmune and signed an agreement with Antigenics concerning the adjuvant QS-21 for use in our HER-2 AutoVac(TM) Protein breast cancer program. Each of these agreements secures us access to technologies that complement and strengthen our proprietary technology platform within immunotherapy."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance